Synthesis and utility of new capgroup largazole analogs
Analogs of largazole are described herein. Methods of treating cancer, blood disorders, autoimmune disease, and Alzheimer's Disease using largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.
1. A compound of Formula (B)
wherein X═NH, or NR, wherein R is H or lower alkyl; wherein R 2 ═H, acyl, or cleavable SR 5 , wherein R 5 =folate, methotrexate, cytokines, peptide, carbohydrate, or another molecule of the same (i.e., resulting in a homodimer); or a pharmaceutically acceptable salt, solvate, clathrate, or stereoisomer thereof.
2. A compound of Formula (C)
wherein X═NH, or NR, wherein R is H or lower alkyl; wherein R 2 ═H, acyl, or cleavable SR 5 , wherein R 5 =folate, methotrexate, cytokines, peptide, carbohydrate, or another molecule of the same (i.e., resulting in a homodimer); or a pharmaceutically acceptable salt, solvate, clathrate, or stereoisomer thereof.
3. A compound having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, clathrate, or stereoisomer thereof.
4. A method for alleviating symptoms of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, renal cancer, prostate cancer, or breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 .
5. The method of claim 4 , wherein the symptoms are of leukemia.
6. The method of claim 4 , further comprising treating said subject with an additional form of therapy for cancer.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient.
8. A composition comprising a radiolabelled compound of claim 1 .
9. A method for alleviating symptoms of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, renal cancer, prostate cancer, or breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 2 .
10. The method of claim 9 , wherein the symptoms are of leukemia.
11. The method of claim 9 , further comprising treating said subject with an additional form of therapy for cancer.
12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 2 and at least one pharmaceutically acceptable excipient.
13. A composition comprising a radiolabelled compound of claim 2 .
14. A method for alleviating symptoms of leukemia, non-small cell lung cancer, colon cancer, central nervous system cancer, renal cancer, prostate cancer, or breast cancer in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 3 .
15. The method of claim 14 , wherein the symptoms are of leukemia.
16. The method of claim 14 , further comprising treating said subject with an additional form of therapy for cancer.
17. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 3 and at least one pharmaceutically acceptable excipient.
18. A composition comprising a radiolabelled compound of claim 3 .